Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Activity of CD44v6 CAR T-cells in AML and MM
NCT04097301Phase 2Terminated
- Sponsor
- AGC Biologics
- Start
- Aug 2019
- Primary completion
- Jun 2021
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of MLM-CAR44.1 T-cells in acute myeloid leukemia (AML), multiple myeloma (MM), sponsored by AGC Biologics. Started Aug 2019; status: terminated.
02
Drugs
MLM-CAR44.1 T-cells
03
Conditions
acute myeloid leukemia (AML)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04097301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097301.